• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583).
  

PubMed=3756862
Maynard K., Parsons P.G.
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Cancer Res. 46:5009-5013(1986)

PubMed=3127479; DOI=10.1111/1523-1747.ep12461022
McEwan M., Parsons P.G., Moss D.J.
Monoclonal antibody against human tyrosinase and reactive with melanotic and amelanotic melanoma cells.
J. Invest. Dermatol. 90:515-519(1988)

PubMed=2798328; DOI=10.1111/j.1600-0749.1989.tb00217.x
Barkla D.H., Allen B.J., Brown J.K., Mountford M.H., Mishima Y., Ichihashi M.
Morphological changes in human melanoma cells following irradiation with thermal neutrons.
Pigment Cell Res. 2:345-348(1989)

PubMed=1697409
Chenevix-Trench G., Martin N.G., Ellem K.A.O.
Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Oncogene 5:1187-1193(1990)

PubMed=7520026; DOI=10.1002/ijc.2910580413
Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.
Expression of the co-stimulatory molecule B7 on melanoma cells.
Int. J. Cancer 58:527-532(1994)

PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Stark M.S., Hayward N.K.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)